Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

741
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
741
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

776
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
776
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

664
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
664
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.4K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.4K
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

852
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
852
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

830
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
830

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treating the sarcomere, respecting the geometry: mitral valve determinants of response to Mavacamten in obstructive hypertrophic cardiomyopathy.

European heart journal. Cardiovascular Imaging·2026
Same author

Left atrial mechanical dispersion as a novel predictor biomarker of new-onset atrial arrhythmias in cardiac amyloidosis.

International journal of cardiology·2026
Same author

Artificial Intelligence-Enhanced Cardiac Point-of-Care Ultrasound: A Prospective Single-Arm Study.

Mayo Clinic proceedings. Digital health·2026
Same author

Cross-sectional evaluation of cardiovascular biological age using point-of-care ultrasound.

European heart journal. Digital health·2026
Same author

Correction: Artificial intelligence assessment of valvular disease and ventricular function by a single echocardiography view.

Frontiers in digital health·2026
Same author

EACVI Survey on the Current Multi-Modality Imaging Practice in Patients with Tricuspid Regurgitation.

European heart journal. Imaging methods and practice·2026

Related Experiment Video

Updated: Apr 7, 2026

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.8K

Dynamic obstruction in hypertrophic cardiomyopathy.

Bogdan A Popescu1, Monica Rosca, Ehud Schwammenthal

  • 1aDepartment of Cardiology, University of Medicine and Pharmacy 'Carol Davila', Euroecolab bInstitute of Cardiovascular Diseases 'Prof. Dr C. C. Iliescu', Bucharest, Romania cHeart Center, Chaim Sheba Medical Center, Tel Hashomer, Tel Aviv University, Israel.

Current Opinion in Cardiology
|July 14, 2015
PubMed
Summary

Echocardiography advances offer new insights into hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction. Novel techniques improve understanding, prognosis assessment, and interventional guidance for HCM patients.

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.4K
An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

6.3K

Related Experiment Videos

Last Updated: Apr 7, 2026

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.8K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.4K
An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

6.3K

Area of Science:

  • Cardiology
  • Medical Imaging
  • Biomedical Engineering

Background:

  • Hypertrophic cardiomyopathy (HCM) is often associated with left ventricular outflow tract (LVOT) obstruction.
  • Accurate assessment of LVOT obstruction is crucial for patient management and prognosis.

Purpose of the Study:

  • To review recent advances in echocardiographic assessment of LVOT obstruction in HCM.
  • To highlight novel imaging techniques and their role in understanding obstruction pathophysiology.
  • To discuss the prognostic value of exercise echocardiography and image-guided interventions.

Main Methods:

  • Review of recent literature on echocardiographic techniques for LVOT obstruction in HCM.
  • Focus on novel technologies like vector flow mapping and myocardial contrast perfusion imaging.
  • Analysis of data from exercise echocardiography and image-guided interventional procedures.

Main Results:

  • Novel echocardiography technologies provide deeper insights into the mechanisms of dynamic LVOT obstruction.
  • Exercise echocardiography demonstrates prognostic value in HCM patients.
  • Myocardial contrast perfusion imaging aids in guiding alcohol septal ablation procedures.

Conclusions:

  • Echocardiography is a versatile tool for evaluating dynamic LVOT obstruction in HCM.
  • It offers insights into pathophysiology, clinical impact, and guidance for interventional relief.
  • Continuous evolution of echocardiography enhances its utility in managing HCM.